Antiepileptic drug treatment in children

Expert Review of Neurotherapeutics

Volumn 7, Issue 2, 2007, Pages 179-193

  Hadjiloizou, Stavros M ^a   Bourgeois, Blaise F D ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Childhood epilepsy; Epilepsy treatment

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CORTICOTROPIN; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MIDAZOLAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RUFINAMIDE; STEROID; SULTIAME; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; VITAMIN D; ZONISAMIDE;

ABSENCE; ADJUVANT THERAPY; ALOPECIA; ANHIDROSIS; ANOREXIA; APLASTIC ANEMIA; APPETITE; ASTHENIA; ATAXIA; ATTENTION; BEHAVIOR CHANGE; BENIGN CHILDHOOD EPILEPSY; BLOOD CLOTTING DISORDER; BLURRED VISION; BONE DEFECT; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CEREBELLUM ATROPHY; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; COORDINATION DISORDER; DEPRESSION; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; EPILEPTIC STATE; EXCITEMENT; FACE DYSMORPHIA; FATIGUE; FEBRILE CONVULSION; FEVER; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAND MAL SEIZURE; HEADACHE; HEMATOLOGIC DISEASE; HEMORRHAGIC PANCREATITIS; HICCUP; HIRSUTISM; HUMAN; HYPERACTIVITY; HYPERAMMONEMIA; HYPERKINESIA; HYPERSENSITIVITY REACTION; HYPERTHERMIA; HYPOCALCEMIA; HYPONATREMIA; INFANTILE SPASM; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INSOMNIA; KIDNEY DISEASE; LANDAU KLEFFNER SYNDROME; LENNOX GASTAUT SYNDROME; LETHARGY; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; METABOLIC ACIDOSIS; MONOTHERAPY; MOOD CHANGE; MOTOR DYSFUNCTION; MYOCLONUS SEIZURE; NAUSEA; NEPHROLITHIASIS; OPTIC DISK ANOMALY; OSTEOMALACIA; PARESTHESIA; PROGNOSIS; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; RETINA GYRATE ATROPHY; REVIEW; SEDATION; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SWEATING; TACHYPNEA; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREMOR; VISUAL FIELD DEFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; CHILD; CLASSIFICATION; DRUG INDUSTRY; EPILEPSY; METHODOLOGY; PATHOPHYSIOLOGY; PEDIATRICS;

ANTICONVULSANTS; CHILD; DRUG INDUSTRY; EPILEPSY; HUMANS; PEDIATRICS; QUALITY OF LIFE;

EID: 33847319697     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.2.179     Document Type: Review

References (114)

1. Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert Rev. Neurother. 6, 397-406 (2006).
2. Pellock JM, Watemberg N. New antiepileptic drugs in children: present and future. Semin. Pediatr. Neurol. 4, 9-18(1997).
3. French JA, Kanner AM, Bautista J et al. American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee; American Epilepsy Society Quality Standards Subcommittee. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology 62, 1252-1260 (2004). • Evidenced-based assessment of the efficacy, tolerability and safety of antiepileptic drugs in the treatment of newly diagnosed epilepsy. The same article is also published in Epilepsia 45, 401-409 (2004).
4. Bourgeois BF. Childhood epilepsy: pharmacological considerations. Acta Neurol. Scand. Suppl. 140, 23-27 (1992).
5. Bryant A, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 46, 465-469 (1996).
6. Messenheimer JA, Guberman AH. Rash with lamotrigine: dosing guidelines. Epilepsia 41, 488 (2000).
7. Asconape JJ, Penry JK, Dreifuss FE, Riela A, Mirza W. Valproate-associated pancreatitis. Epilepsia 34, 177-183 (1993).
8. Bourgeois BF. Determining the effects of antiepileptic drugs on cognitive function in pediatric patients with epilepsy. J. Child Neurol. 19(Suppl. 1), S15-S24 (2004). • Overview of the cognitive effects of antiepileptic drugs in children.
9. Sazgar M, Bourgeois BF. Aggravation of epilepsy by antiepileptic drugs. Pediatr. Neurol. 33, 227-234 (2005). • Highlights the clinical circumstances of seizure exacerbation by antiepileptic drugs and discusses their potential mechanisms.
10. Somerville ER. Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials? Neurology 59, 79-83 (2002).
11. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 55, 1106-1109 (2000).
12. Carrazana EJ, Wheeler SD. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 56, 1424-1425 (2001).
13. Biraben A, Allain H, Scarabin JM, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 55(11), 1758 (2000).
14. Bourgeois BF. Reducing overtreatment. Epilepsy Res. 52, 53-60 (2002).
15. Bourgeois BF. New antiepileptic drugs in children: which ones for which seizures? Clin. Neuropharmacol. 23, 119-132 (2000).
16. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 37(Suppl. 6), S4-S11 (1996).
17. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2, 347-356 (2003). • Comprehensive review of the clinically important drug interactions in epilepsy.
18. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38, 859-880 (1997).
19. Bourgeois BF. New antiepileptic drugs. Curr. Opin. Pediatr. 8, 543-548 (1996).
20. Farwell JR, Lee YJ, Hirtz DG et al. Phenobarbital for febrile seizures - effects on intelligence and on seizure recurrence. N. Engl. J. Med. 322, 364-369 (1990).
21. Riva D, Devoti M. Discontinuation of phenobarbital in children: effects on neurocognitive behavior. Pediatr. Neurol. 14, 36-40 (1996).
22. Camfield CS, Chaplin S, Doyle AB et al. Side effects of phenobarbital in toddlers: behavioral and cognitive aspects. J. Pediatr. 95, 361-365 (1979).
23. Hahn TJ. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N. Engl. J. Med. 292, 550 (1975).
24. Greenlaw R. Osteomalacia (OM) from anticonvulsant (ACV) drugs: therapeutic implications. Clin. Res. 20, 427 (1972).
25. Kilarski DJ, Buchanan C, Behren LV. Soft-tissue damage associated with intravenous phenytoin. N. Engl. J. Med. 311, 1186-1187 (1984).
26. Leppik IE, Boucher BA, Wilder BJ et al. Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients. Neurology 40, 456-460 (1990).
27. Johannessen SI. Laboratory monitoring of antiepileptic drugs. In: Antiepileptic Drugs (4th Edition). Levy RH, Mattson RH, Meldrum BS (Eds). Raven Press, NY, USA, 179-187 (1995).
28. Yaari Y, Selzer ME, Pincus JH. Phenytoin: mechanisms of its anticonvulsant action. Ann. Neurol. 20, 171-184 (1986).
29. Anast CS. Anticonvulsant drugs and calcium metabolism. N. Engl. J. Med. 292, 587 (1975).
30. Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, doubleblind, placebo-controlled study. Sulthiame Study Group. Epilepsia 41(10), 1284-1288 (2000).
31. Wirrell E, Ho AW, Hamiwka L. Sulthiame therapy for continuous spike and wave in slow-wave sleep. Pediatr. Neurol. 35, 204-208 (2006).
32. Ben-Zeev B, Watemberg N, Lerman P, Barash I, Brand N, Lerman-Sagie T. Sulthiame in childhood epilepsy. Pediatr. Int. 46, 521-524 (2004).
33. Lerman P, Lerman-Sagie T. Sulthiame revisited. J. Child Neurol. 10, 241 (1995).
34. Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Peadiatr. Drugs 3, 379-403 (2001).
35. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valporate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 29, 147-154 (1998).
36. Snead OC 3rd, Hosey LC. Treatment of epileptic falling spells with ethosuximide. Brain Dev. 9, 602-604 (1987).
37. Oguni H, Uehara T, Tanaka T, Sunahara M, Hara M, Osawa M. Dramatic effect of ethosuximide on epileptic negative myoclonus: implications for the neurophysiological mechanism. Neuropediatrics 29, 29-34 (1998).
38. Hvidberg EF, Dam M. Clinical pharmacokinetics of anticonvulsants. Clin. Pharmacokinet. 1, 161 (1976).
39. Mattson RH, Cramer JA. Valproic acid and ethosuximide interaction. Ann. Neurol. 7, 583-584 (1980).
40. Bourgeois BF. Felbamate. Semin. Pediatr. Neurol. 4, 3-8 (1997).
41. Rho JM, Donevan DS, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D- aspartate and γ-aminobutyric acid A receptors. Ann. Neurol. 35, 229-234 (1994).
42. Leppik IE, Graves N, Devinsky O. New antiepileptic medications. Neurol. Clin. 11, 923-950 (1993).
43. Burdette DE, Zheng C, Tornow MA et al. Felbamate reduces atypical generalized spike wave discharges in patients with Lennox-Gastaut syndrome. Neurology 42(Suppl. 3), 330 (1992).
44. Kelley MT, Walson PD, Cox S, Dusci LJ. Population pharmacokinetics of felbamate in children. Ther. Drug Monit. 19(1), 29-36 (1997).
45. Pellock JM. Felbamate in epilepsy therapy. Evaluating the risks. Drug Saf. 21, 225-239 (1999).
46. Anon. Recommendation for the immediate withdrawal of patients from treatment with Felbatol(R) (felbamate). FDA Medical Bulletin 24(No. 2), 5 (1994).
47. Pellock JM, Brodie MJ. Felbamate: update. Epilepsia 38(12), 1261-1264 (1997).
48. Chadwick DW, Anhut H, Greiner MJ et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-977. Neurology 51, 1282-1288 (1998).
49. Trudeau V, Myers S, LaMoreaux L, Anhut H, Garofalo E, Ebersole J. Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J. Child Neurol. 11, 470-475 (1996).
50. Bourgeois B, Brown LW, Pellock JM et al. Gabapentin (Neurontin®) monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS): a 36-week, double-blind, placebo-controlled study [abstract]. Epilepsia 39(Suppl. 6), 163 (1998) (Abstract 5.067).
51. Andrews CO, Fischer JH. Gabapentin: a new agent for the management of epilepsy. Ann. Pharmacother. 28(10), 1188-1196 (1994).
52. Tatum WO 4th, Zachariah SB. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology 45, 1216-1217 (1995).
53. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr. Notrieurol. 23, 160-163 (2000).
54. Culy CR, Goa KL. Lamotriginre. A review of its use in childhood epilepsy. Pediatr. Drugs 2, 299-330 (2000).
55. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N. Engl. J. Med. 337(25), 1807-1812 (1997).
56. Frank LM, Enlow T, Holmes GL et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 40, 973-979 (1999).
57. Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia 45, 1049-1053 (2004).
58. Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 65(11), 1737-1743 (2005).
59. Guberman AH, Besag FMC, Brodie MJ et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 40, 985-991 (1999).
60. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann. Pharmacother. 33(10), 1037-1042 (1999).
61. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 345, 476-479 (1995).
62. Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 39(12), 1324-1328.
63. Biton V, Bourgeois BF; YTC/YTCE Study Investigators. Topiramate in patients with juvenile myoclonic epilepsy. Arch. Neurol. 62, 1705-1708 (2005)
64. Takeoka M, Holmes GL, Thiele E et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia 42, 387-392 (1998).
65. Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 43, 744-777 (2002).
66. Arcas J, Ferrer T, Roche MC, Martinez-Bermejo A, Lopez-Martin V. Hypohidrosis related to the administration of topiramate to children. Epilepsia 42(10), 1363-1365 (2001).
67. Meldrum BS, Chapman AG. Basic mechanisms of Gabitril (tiagabine) and future potential developments. Epilepsia 40(Suppl. 9), S2-S6 (1999).
68. Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia 40(Suppl. 9), S7-S13 (1999).
69. Schapel G, Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure 5, 153-156 (1996).
70. Ettinger AB, Bernal OG, Andriola MR et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia 40, 1159-1162 (1999).
71. Mackay M, Weiss S, Snead OC 3rd. Treatment of infantile spasms: an evidence-based approach. Int. Rev. Neurobiol. 49, 157-184 (2002). • Evidence-based review of the treatment of infantile spasms.
72. Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, Logan WJ. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111(10), 1935-1942 (2004).
73. Rigolet MH, Baulac M, Nordmann JP. Electrophysiological monitoring of epileptic patients treated with vigabatrin. J. Fr. Ophtalmol. 28, 635-641 (2005).
74. Miller NR. Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants. Neurology 55(3), 333-334 (2000).
75. Gallagher MJ, Eisenman LN, Brown KM et al. Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy. Epilepsia 45, 90-91 (2004).
76. Krauss GL, Betts T, Abou-Khalil B, Gergey G, Yarrow H, Miller A. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 12, 617-620 (2003).
77. Cavitt J, Privitera M. Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. Arch. Neurol. 61(10), 1604-1607 (2004).
78. Patsalos PN. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia 46(Suppl. 9), 140-148 (2005).
79. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet. 43(11), 707-724 (2004).
80. Vigevano F. Levetiracetam in pediatrics. J. Child Neurol. 20, 87-93 (2005).
81. Bill PA, Vigonius U, Pohlmann H et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 27, 195-204 (1997).
82. Christe W, Kramer G, Vigonius U et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 26, 451-460 (1997).
83. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 3, 70-76 (1989).
84. Tecoma ES. Oxcarbazepine. Epilepsia 40(Suppl. 5), S37-S46 (1999).
85. Bourgeois BF, D'Souza J. Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience. Epilepsy Behav. 7, 375-382 (2005).
86. Sakamoto K, Kurokawa T, Tomita S et al. Effects of zonisamide on children with epilepsy. Curr. Therapeut. Res. 13, 378-383 (1988).
87. Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J. Child Neurol. 17, 87-96 (2002).
88. Bourgeois BF. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology 55(Suppl. 3), S11-S16 (2000).
89. Low PA, James S, Peschel T, Leong R, Rothstein A. Zonisamide and associated oligohidrosis and hyperthermia. Epilepsy Res. 62, 27-34 (2004).
90. Arroyo S, Anhut H, Kugler AR et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45, 20-27 (2004).
91. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 42, 790-792 (2001).
92. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45(Suppl. 6), 13-18 (2004).
93. Brodie MJ, French JA. Role of levetiracetam in the treatment of epilepsy. Epileptic Disord. 5(Suppl. 1), S65-S72 (2003).
94. Morrell MJ. Antiepileptic medications for the treatment of epilepsy. Semin. Neurol. 22, 247-258 (2002).
95. Bourgeois BF. Chronic management of seizures in the syndromes of idiopathic generalized epilepsy. Epilepsia 44(Suppl. 2), 27-32 (2003). • Stematic review of evidence-based data to guide the treatment of idiopathic generalized epilepsy, while avoiding seizure aggravation.
96. Sato S, White BG, Penry JK, Dreifuss FE, Sackellares JC, Kupferberg HJ. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 32, 157-163 (1982).
97. Callaghan N, O'Hare J, O'Driscoll D, O'Neill B, Daly M. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev. Med. Child Neurol. 24, 830-836 (1982).
98. Villarreal HJ, Wilder BJ, Willmore LJ, Bauman AW, Hammond EJ, Bruni J. Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 28, 886-891 (1978).
99. Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker GA Liverpool and Manchester Neurodevelopment Study Group. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 64, 949-954 (2005).
100. Astradsson A, Olafsson E, Ludvigssion P et al. Icelandic epilepsy: an incidence study in Iceland. Epilepsia 39, 884-886 (1998).
101. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30, 389-399 (1989).
102. Nicolai J, Aldenkamp AP, Arends J, Weber JW, Vles JS. Cognitive and behavioral effects of nocturnal epileptiform discharges in children with benign childhood epilepsy with centrotemporal spikes. Epilepsy Behav. 8, 56-70 (2006).
103. Tzitiridou M, Panou T, Ramantani G, Kambas A, Spyroglou K, Panteliadis C. Oxcarbazepine monotherapy in benign childhood epilepsy with centrotemporal spikes: a clinical and cognitive evaluation. Epilepsy Behav. 7, 458-467 (2005).
104. Mitsudome A, Ohfu M, Yasumoto S et al. The effectiveness of clonazepam on the Rolandic discharges. Brain Dev. 19, 274-278 (1997).
105. Bast T, Volp A, Wolf C, Rating D. Sulthiame Study Group. The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS). Epilepsia 44, 215-220 (2003).
106. Mackay MT, Weiss SK, Adams-Webber T et al. American Academy of Neurology; Child Neurology Society. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 62(10), 1668-1681 (2004). • Evaluates the current clinical evidence in the treatment of infantile spasms to determine the best practice for treatment.
107. French JA, Kanner AM, Bautista J, Abou-Khalil B et al. American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee; American Epilepsy Society Quality Standards Subcommittee. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45, 410-423 (2004). • Evidenced-based assessment of the efficacy, tolerability and safety of antiepileptic drugs in the treatment of refractory epilepsy.
108. Tassinari CA, Dravet C, Roger J, Cano JP, Gastaut H. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 13, 421-435 (1972).
109. DiMario FJ Jr, Clancy RR. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediatr. Neurol. 4, 249-251 (1988).
110. Horn CS, Ater SB, Hurst DL. Carbamazepine-exacerbated epilepsy in children and adolescents. Pediatr. Neurol. 2, 340-345 (1986).
111. Glauser T, Gerhard Kluger, Rajesh Sachedo et al. Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial: LBS.001 Neurology 64, 1826-1988 (2005).
112. Frost M, Gates J, Helmers SL, Wheless JW et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia 42, 1148-1152 (2001).
113. Painter MJ, Scher MS, Stein AD et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N. Engl. J. Med. 341, 485-489 (1999).
114. Hadjiloizou SH, Riviello JJ. Epileptic and Epileptiform Encephalopathies May (2006) www.emedicine.com/neuro/topic547.html